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African trypanosomiasis is a parasitic disease affecting 5000 humans and millions of livestock animals in
sub-Saharan Africa every year. Current treatments are limited, difﬁcult to administer and often toxic
causing long term injury or death in many patients. Trypanosome alternative oxidase is a parasite
speciﬁc enzyme whose inhibition by the natural product ascofuranone (AF) has been shown to be
curative in murine models. Until now synthetic methods to AF analogues have been limited, this has
restricted both understanding of the key structural features required for binding and also how this
chemotype could be developed to an effective therapeutic agent. The development of 3 amenable novel
synthetic routes to ascofuranone-like compounds is described. The SAR generated around the AF che-
motype is reported with correlation to the inhibition of T. b. brucei growth and corresponding selectivity
in cytotoxic assessment in mammalian HepG2 cell lines. These methods allow access to greater synthetic
diversiﬁcation and have enabled the synthesis of compounds that have and will continue to facilitate
further optimisation of the AF chemotype into a drug-like lead.
© 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
African Trypanosomiasis is a parasitic protozoan infection in
mammals spread by the tsetse ﬂy (Glossina) [1]. It is exclusively
found in 36 sub-Saharan African countries between 14N and 20S
[2]. Trypanosoma brucei gambiense and T. b. rhodesiense cause the
chronic western and acute eastern infections respectively, these
two species have developed strategies to neutralize the immunity
conferred by apolipoprotein A1, a trypanosomal lytic factor (TLF) in
normal human sera [3], and evade host immune response by
antigenic variation of their variant surface glycoprotein coat [4]. 60
million people are at risk of human African trypanosomiasis (HAT)
with 5000 new cases reported annually [5,6]. Stage 1 of the disease
is haemolymphatic [7], subsequent penetration into the brain gives
rise to stage 2 where meningoencephalitis and neuronalce, Cardiff, CF10 3AT, UK.
.
r Masson SAS. This is an open accedestruction produce a diverse range of symptoms including motor
neuropathy, psychiatric disorders, sensory disturbances and the
characteristic disruption of the diurnal cycle causing lethargy and
insomnia that gives the disease its sleeping sickness title [8].
Without chemotherapeutic intervention the disease progresses to
coma and death in almost all cases [9]. The high morbidity is
evinced by the 1.79 million disability-adjusted life years (DALYs)
calculated for HAT, over ﬁve times greater than that for the related
disease leishmaniasis [10]. This infection is not limited to humans;
animal African trypanosomiasis (AAT) is the single largest infection
of cattle in Africa necessitating 35 million doses of trypanocidal
agents, costing up to 140 million USD annually and impacting
nutrition, livelihoods and development across sub-Saharan Africa.
[11,12] Different trypanosome species affect cattle, predominantly
T. vivax, T. evansi and T. congolense [13]. AAT is less often fatal but its
characteristic anaemia [14] severely impairs the health and pro-
ductivity of cattle.
Current treatments for HAT are far from ideal: stage 1 treat-
ments pentamidine and suramin (Fig. 1) only treat one subspecies
(T.b. gambiense and T.b. rhodesiense respectively) and requiress article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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stage 2 is limited to nifurtimox-eﬂornithine combination therapy
(NECT) and melarsoprol where NECT is ineffective in treating T.b.
rhodesiense infection [15]. All current treatments are of limited
utility due to signiﬁcant toxicities; the organoarsenide melarsoprol
even causes reactionary encephalitis in 10% of patients and death in
5%. [16,17] The treatments all require clinicians for IV/IM injections
[15], which is a major practical impediment for a diffuse population
over a sizable portion of continental Africa. Drug resistance for
melarsoprol and pentamidine has been increasingly observed [18]
and has been linked to mutated aquaglyceroproteins both in vitro
and in ﬁeld isolates, required for trypanosomal uptake of the
compounds [19].
With such poor therapeutics currently available, it is imperative
that new, improved drug agents are discovered. An excellent target
for drug development is trypanosome alternative oxidase (TAO).
TAO is a ubiquinol dependent terminal oxidase required for the
long slender blood stream trypanosomes aerobic glucose meta-
bolism converting oxygen into water [20]. It is a 38 kDa cyanide-
insensitive mitochondrial inner-leaf protein with a di-iron core
which is key for enzymatic activity [21]. Many factors make it an
exciting drug development target: 1) TAO is expressed in only
parasitic organisms with no mammalian homologues [22]; 2)
biochemical assays are well established [23]; 3) the crystal struc-
ture has been determined [24]; 4) inhibition of TAO has demon-
strated clear trypanocidal action [25]; 5) existence of potent natural
product inhibitors of TAO, in particular ascofuranone (AF) with
Ki ¼ 0.13 nM [26]; 6) demonstration of efﬁcacy with ascofuranone
in vitro and murine in vivo models [25,27].
However, ascofuranone-like inhibitors have many undesirable
qualities associated with their chemical structure. In particular, the
electron rich aromatic ring, pendant aldehyde, phenols and lipo-
philic side chain contribute to the rapid observed clearance, low
oral bioavailability and potential toxicity of this class. Furthermore,
structure activity relationships (SAR) published around the geranyl
tail clearly demonstrate that its effects are almost entirely due to
non-speciﬁc lipophilic interactions.
Although TAO represents an attractive target for treating HAT,
no real progress has been made in the development of potential
drug agents from this chemical start point, despite the fact that AF
has been known for over 20 years to be a potent inhibitor both
in vitro and in vivo. [27,28] One of the major bottlenecks to this
progress has been lack of versatility of the available synthetic
routes to these templates. There are only a handful of published
synthetic methods, all suffering from linear sequence of steps
resulting in poor overall yields [29]. [30] Additionally, our group has
not been able to reproduce all of the chemistry reported to date.
One key limitation of the current methodologies is that they rely on
pre-formation of the penta-substituted aromatic head group,
which is low-yielding and has limited potential for SAR expansion.Fig. 1. Current HAT treatments.The subsequent addition of the side chain is also capricious and low
yielding. The reported deprotonation [31] with KOH followed by
addition of geranyl bromide yielded only 5% product whilst other
non-prenyl bromides preferably undergo O-alkylation. The selec-
tion of an appropriate protecting group for the bis-phenol 2 proved
challenging as some silicon ethers or esters are labile in the pres-
ence of the ortho-aldehyde. The reported double SEM [32] protec-
tion of phenols in compound 3with subsequent tail-chain addition
via lithium halogen exchange was poor yielding, and subsequent
removal of the SEM ethers proved impossible. Compound 2 does
not undergo palladium-mediated coupling reactions, presumably
due to the exposed phenols. Suzuki coupling is possible with
methylated phenols but deprotection remains an impasse.
We report here a series of novel, simpliﬁed and improved syn-
thetic routes to AF-like compounds. Two of the routes we have
developed allow facile diversiﬁcation of the head group that con-
fers activity as well as alteration of the tail. We also report TAO
inhibition data for the molecules prepared during these synthetic
investigations. This will build upon the existing SAR platform
around the active head group to help inform future development of
AF-like TAO inhibitors for HAT.2. Results and discussion
2.1. Synthetic chemistry
Previous attempts to deprotect the bis-protected phenol ethers
(Fig. 2) was found to only remove protecting groups ortho to the
aldehyde. This was likely due to an enhanced bidentate chelation of
Lewis acids available to this motif, this chelation could destabilise
the etheric C-O bond and allow for its removal. To take advantage of
this, Lewis-acid mediated cationic rearrangement of the prenyl
chain was employed [33]. It was necessary to mask the para phenol
as the acetate, to enable the rearrangement, as the unprotected
para phenol substrate did not rearrange. Compound 5 was rear-
ranged to give colletochlorin B (CCB-6) a proven trypanocide and
potent TAO inhibitor (IC50e2 nM) in a yield which, although
modest, was a signiﬁcant improvement over past reports. This
chemistry was subsequently employed to generate compounds in
the following SAR investigation (see Scheme 1).
Exploiting the reactivity of the phenolic functionality had
proven successful and was explored further. When starting from
orcinol, double protection of the phenols as MOM ethers was
required to allow the reaction of alkyl bromides via lithiation and
subsequent electrophilic aromatic substitution (exempliﬁed by
DMF in Scheme 2) in excellent yields. This alkylationwas attempted
with the geranyl chain, giving an overall 48% yield via sequential
one-pot additions. However, removal of the protecting groups was
again challenging yielding only 15% product. This method for
addition of the sidechain takes advantage of the symmetrical
starting material thus removing the regioselectivity issues from the
subsequent additions.
Further lithiation chemistry gave access to differentiated core
structures through more ﬂexible synthetic routes, however sub-
sequent optimisation was required to improve both overall yields
and increase structural diversity (Scheme 3). Starting from theFig. 2. Ascofuranone and previous synthetic starting points.
Scheme 1. Lewis acid catalysed synthesis: a) NEt3, AcCl, CH2Cl2, 68%; b) geranyl bro-
mide, K2CO3, KI, DMF, 50%; c) Florisil, toluene, 28%; d) NaOH, THF/MeOH, 97%.
Scheme 2. Ortho-lithiation syntheses: a) NaH, MOMCl, DMF, 93%; b) 1) n-BuLi, geranyl
bromide, THF 2) n-BuLi, DMF, 48%; c) n-BuLi, bromooctane, THF, 0 C, 95%; d) ethylene
glycol, mw 160 C, 98%; e) POCl3, DMF, 96%; f) SO2Cl2, CH2Cl2, quant.
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late stage diversiﬁcation. Protection as the enol methyl ether 14 or
15 ensured clean formation of the desired enolate. This readily
underwent substitution at the a-carbon. Oxidation by DDQ and
subsequent de-protection afforded the AF-like analogues 18 and 19.
A range of diverse analogues have been prepared with the
chemistry described and are currently under biological investiga-
tion, data will be reported in future publications. These synthetic
methods represent a signiﬁcant improvement over previously re-
ported methodologies and allow access to a range of diverse, novel
AF-analogues. This work will facilitate the exploration of this che-
motype to generate more drug like TAO inhibitors for future
development.2.2. Protein expression and puriﬁcation
Recombinant TAO was expressed in Rosetta2® E. coli byScheme 3. Diversiﬁable synthesis: a) NaH, tBu-acrylate, DMF, 80 C, 95%, b) octanal, L-
proline, NaBH3CN, EtOH, quant; c) SO4Me2, NaH, THF, 95%; d) LDA, methyl formate,
THF, 78 C, 64%; e) DDQ, CH2Cl2, 84%.transformation of plasmid containing complementary DNA for the
overexpression of His-tagged trypanosome alternative oxidase,
obtained from Anthony Moore, University of Sussex. Subsequent
culture in LB broth, containing 120 g/L sorbitol and 250 mM
betaine, 50 mg/mL ampicillin and 35 mg/mL chloramphenicol,
grown at 37 C until OD600 0.2 then grown at 18 C until OD600 0.6
was reached. The culture was induced with the addition of Iso-
propyl b-D-1-thiogalactopyranoside 500 mM ﬁnal concentration
and the cultures continued overnight at 18 C. The E. coli pellet was
isolated by centrifugation 10000g for 20 min at 4 C (Beckman
Coulter Avanti J26S, JLA9.1000 rotor). Lysis was carried out by re-
suspension of the pellet in 50 mL of lysis buffer (50 mM Tris HCl,
20% (w/v) sucrose pH 7.4, 1 protease inhibitor cocktail tablet and
2 mL of Benzonase/DNAse® Sigma) and sonication (Sonics Vibracell,
13 mm probe, 35% intensity, 180 s, 5 s pulses). Cell debris and un-
broken cells were removed by centrifugation (Beckman Coulter
Avanti J26S, JA 25.50 rotor, 8000 g, 10 min, 4 C) to provide the
supernatant as the crude fraction for further puriﬁcation.
Fractionation of the E. coli inner membranes was performed by
isopycnic centrifugation. The crude supernatant was overlaid onto
45% sucrose solution (3 20mL, 50mM TrisHCl, 45% (w/v) sucrose,
pH 7.4) and ultra-centrifuged (Beckman Coulter L-80, SW28,
141000 rcf max, 1 h, 4 C) to isolate the E. coli inner membranes as
the buoyant supernatant fraction. The supernatant from this was
diluted 1:1 (50 mM Tris HCl, pH 7.4) to give a 15e20% sucrose so-
lution reducing the density of the media and enabling the sedi-
mentation of the inner membranes as a pellet by further
ultracentrifugation (Beckman Coulter L-80, SW28, 141000 rcf max,
1 h, 4 C). The inner membrane pellet was solubilised by re-
suspension with octylglucopyranoside (OG) buffer (37 mL, 50 mM
TrisHCl, 1.4% OG (w/v), 20% glycerol (v/v), 200 mM MgSO4, pH 7.4)
followed by ultra-centrifugation (Beckman Coulter L-80, SW28,
141000 rcf max, 1 h, 4 C) to remove non solubilised protein and
debris. Puriﬁcation of the solubilsed membrane fraction was per-
formed by cobalt afﬁnity chromatography (TALON® resin). The
column was equilibrated with buffer (50 mL, 20 mM Tris HCl, 1.4%
OG, 20% glycerol, 100 mM MgSO4 pH 7.4). The resin was incubated
with the solubilised supernatant for 30 min on a roller shaker at
4 C. The ﬂow throughwas collected and the resinwaswashedwith
buffer 1 (2 50 mL 20mM TrisHCl, 20 mM imidazole, 0.042% (w/v)
n-dodecyl-b-D-maltopyranoside (DDM), 20% (v/v) glycerol, 50 mM
MgSO4, pH 7.4) and buffer 2 (1  50 mL 20 mM TrisHCl, 160 mM
imidazole, 0.042% (w/v) n-dodecyl-b-D-maltopyranoside (DDM),
20% (v/v) glycerol, 50 mM MgSO4, pH 7.4). rTAO was then eluted
with elution buffer (10 10 mL 20 mM TrisHCl, 200 mM imidazole,
0.042% (w/v) n-dodecyl-b-D-maltopyranoside (DDM), 20% (v/v)
glycerol, 50 mM MgSO4, 60 mM NaCl, pH 7.4). Concentration of
these fractions through a 10 kDa molecular weight cut off Amicon
Ultra-15 ﬁlter unit provided TAO enzyme for use in absorbance
inhibition assay, lane 2 Fig. 4. AOX conﬁrmed in Western Blot
analysis using Polyclonal Ab from Agrisera (raised against plant
AOX1/AOX2 (AS04 054) >70% homology to TAO) (lane 3 Fig. 3).
Both bands observed at 37 kDa and 74 kDa in SDS-PAGE (lane 2)
were conﬁrmed to be rTAO by in-gel trypsin digest and analysis by
protein mass spec (data not shown).
2.3. TAO activity assay
The assessment of enzymatic activity of puriﬁed rTAO was car-
ried out by monitoring the production of 1-ubiquinone from the
substrate 1-ubiquinol. This modiﬁed substrate was used over the
endogenous substrate as it has a higher aqueous solubility and al-
lows assessment of enzyme activity at higher substrate concen-
trations. The measurement of 1-ubiquinone productionwas carried
out kinetically by absorbance readings at the substrates lambda
Fig. 3. SDS-PAGE and Western analysis of rTAO with Quick Coomassie stain (Generon
QC154201/008). 1 Molecular weight markers, 2 Concentrated puriﬁed rTAO protein, 3
WB 100 ng protein load. Polyclonal Ab from Agrisera (raised against plant AOX1/AOX2
(AS04 054) >70% homology to TAO).
Fig. 4. Michalis-Menten kinetics of rTAO. Data plotted is the mean of 3 independent
experiments each with triplicate points for each condition. The error plotted is the SEM
of the 3 independent experiments. The relative background turnover of substrate
without enzyme was subtracted from each condition internally generated within each
experiment in triplicate. 3 nM of puriﬁed rTAO was used. Graph generated in GraphPad
Prism®.
Fig. 5. IC50 data for colletochlorin B from 4 parameter logistic regression of 10 point
inhibitory concentration data. Data from 3 independent experiments reported con-
centrations run in duplicate per experiment, SEM plotted of experiments. 3 nM of
R.A. West et al. / European Journal of Medicinal Chemistry 141 (2017) 676e689 679max at 278 nm over time. Measurements were taken using assay
buffer containing detergent C10E8 previously identiﬁed in assay
optimisation experiments reported by Kido et al. [23] and 50 mM
Tris buffer.
The Michalis-Menten kinetics of the puriﬁed enzyme was
measured to determine the most suitable substrate concentration
for use in screening activities. Interestingly we observed a Km of
16.5 mM which is notably lower than previous reports [23,34].
Within our experiments we observed that kinetic measurements of
product formation at high substrate concentrations (>250 mM)
showed substantial rates of turnover. This was also observed in
control experiments of substrate turnover without enzyme. If
background subtractions of substrate turnover without enzyme
were not performed calculations of Km showed to be in line with
the previously reported ﬁgures for Km (A - Fig. 4). We therefore
carried out background subtractions of turnoverwithout enzyme at
each concentration of substrate to generate Michalis-Menten Km
calculations of enzyme alone (B - Fig. 4).
In IC50 determination and in screening activities ﬁnal concen-
trations of 3 nM of puriﬁed rTAOwere used with 15 mM1-ubiquinol
for a sufﬁcient window to assess the inhibitory activity of syn-
thesised analogues. Using a substrate concentration close to the
measured Km also enables the identiﬁcation of competitive, non-
competitive and uncompetitive types of inhibitors. We carried
out ten-point IC50 determinations with puriﬁed rTAO protein to try
to understand the action of these compounds. Example data for the
natural product CCBe 6 is shown below (Fig. 5). With correlation to
the ex vivo of inhibition of the growth of T. b. brucei. (Fig. 6).
To understand the mechanism of TAO inhibition by
puriﬁed rTAO was used.
Fig. 6. IC50 data for concentration of colletochlorin B required to inhibit 50% growth of
T. b. brucei Lister427, following incubation with compound for 48 h. Growth inhibition
was measured by quantifying ATP levels. 4 parameter logistic regression of 10 point
inhibitory concentration data. Data from 3 independent experiments reported con-
centrations run in duplicate per experiment, SEM plotted of experiments.
Fig. 7. Michalis-Menten inhibitor kinetics of rTAO, in presence of increasing concen-
tration of inhibitor CCB. Data plotted is the mean of 3 independent experiments each
with triplicate points for each condition. The error plotted is the SEM of the 3 inde-
pendent experiments. The relative background turnover of substrate without enzyme
was subtracted from each condition internally generated within each experiment in
triplicate. 2 nM of puriﬁed rTAO was used. Graph generated in GraphPad Prism®.
Table 1
Summary of modiﬁcations to the aromatic head group.
# R1 R2 R3 TAO inhibition (pIC50)a T.b.b. Growth
Inhibition
(pIC50)b
HepG2 Cytotox
(pCC50)c
6 OH Cl Me 8.4 ± 0.3 8.5 ± 0.1 5.1 ± 0.1
20 OAc Cl Me 6.5 ± 0.2 7.4 ± 0.7 4.8 ± 0.1
21 OH Cl H 7.0 ± 0.2 6.6 ± 0.1 <4.8
22 OAc Cl H 6.3 ± 0.1 6.2 ± 0.1 4.6 ± 0.1
23 OH H Me 5.5 ± 0.2 5.8 ± 0.1 4.4 ± 0.1
24 OAc H Me 5.4 ± 0.1 e e
25 OH H H 5.4 ± 0.2 e e
26 OAc H H 5.5 ± 0.1 e e
27 H Cl H 5.4 ± 0.1 e e
28 OH H OH 5.5 ± 0.1 e e
a Negative log concentration and standard deviation of compounds required for
50% inhibition of trypanosome alternative oxidase.
b Negative log concentration and standard deviation of compounds required for
50% growth inhibition of T. b. brucei Lister427.
c Negative log concentration and standard deviation of compounds required for
50% growth inhibition of HepG2 cell line.
Fig. 8. Dimethoxy analogue.
R.A. West et al. / European Journal of Medicinal Chemistry 141 (2017) 676e689680colletochlorin B, more thorough experiments were performed,
measuring the velocity of 1-ubiquinol turn over with increasing
concentrations of colletochlorin B at different concentrations of
substrate (Fig. 7). Interestingly this data suggests a mixed type non-
competitive inhibition proﬁle with regard to 1-ubiquinol substrate,
that is in accordance with previous reports by Kido et al. [23] The
apparent afﬁnity of 1-ubiquinol is not affected by increasing con-
centrations of inhibitor as the calculated Km remains similar with
increasing inhibitor concentration. Furthermore the Vmax is
reduced with increasing inhibitor concentration, which together
with the Km observation are suggestive of non-competitive binding
with regards to 1-ubiquinol.
2.4. Structure-activity relationships
At the outset of our research, there was not only a lack of robust
synthetic routes to AF analogues but the basic SAR around the ar-
omatic head group was under explored. Consequently, it was un-
clear which substituents were necessary for activity. Interestinglychlorination at R2 contributes a great deal to the inhibition of TAO.
The des-chloro modiﬁcations to compounds 6 and 20e26 (Table 1)
result in a reduction of 1e3 pIC50 units of potency against the
enzyme, and diminishes selectivity for the growth of the trypano-
some. Compound 23 shows 30 fold selectivity for inhibition of
trypanosome growth compared to that of compound 6 that shows
>500 fold selectivity over HepG2 cytotoxicity. Similarly the pres-
ence of a methyl group at R3 contributes signiﬁcantly to the inhi-
bition of TAO albeit to a lesser extent than that of chloro at R2.
Compound 21 shows reduced inhibition of TAO that results in lower
efﬁcacy for trypanosome growth inhibition and consequently re-
duces the selectivity against the mammalian HepG2 cell to ~60 fold.
Previously published work had shown that electron with-
drawing groups were preferred at R4 [26]. Our results conﬁrm this
with the exception of compound 30 where R4 is methyl. Direct
comparison to compound 20 shows an order loss in potency sug-
gesting that it is not only electron withdrawing groups could be
tolerated in this position. Interestingly replacement of the benzal-
dehyde with nitrile 29 and 30 appeared to be a well-tolerated
modiﬁcation showing similar inhibition against TAO, however a
drop in efﬁcacy was observed against the trypanosome (see
Table 2). One further divergence from the reported pharmacophore
is compound 33 where the hydrogen bond donor of the phenol of
C5 has been removed whilst retaining a modest inhibition of TAO,
suggesting that the interaction with the enzyme at this position
may not be via an essential hydrogen bond (see Fig. 8). This is
supported by inhibition data of compound 35 where the point of
Table 2
Summary of modiﬁcations to the aldehyde.
# R1 R3 R4 TAO inhibition (pIC50)a T.b.b. Growth inhibition (pIC50)b HepG2 Cytotox
(pCC50)c
29 OH Me CN 8.4 ± 0.2 6.4 ± 0.1 4.9 ± 0.1
6 OH Me C¼O 8.5 ± 0.3 8.4 ± 0.1 5.1 ± 0.1
20 OAc Me C¼O 6.5 ± 0.2 7.4 ± 0.7 4.8 ± 0.1
30 OAc Me Me 5.7 ± 0.1 e e
21 OH H C¼O 7.0 ± 0.2 6.6 ± 0.1 <4.8
31 OH H CN 7.6 ± 0.3 5.2 ± 0.1 4.4 ± 0.1
32 OH H C¼NOH 6.1 ± 0.3 5.7 ± 0.1 5.0 ± 0.1
a Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxidase.
b Negative log concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lister427.
c Negative log concentration and standard deviation of compounds required for 50% growth inhibition of HepG2 cell line.
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retains activity against TAO supporting the hypothesis that the
necessity for a hydrogen bond donor at R5 is not a requirement for
TAO inhibition. Ether-linked tails could thus reasonably represent a
group of underexplored TAO inhibitors that are more synthetically
amenable (see Table 3).
In general a reasonable correlation was observed between the
inhibition of TAO and the inhibition of growth of the parasite. The
OAc masked phenol in compound 20 showed higher inhibitory
activity against T. b. brucei than expected. This higher than expected
potency could be from the cleavage of the acetate to the free phenol
compound 6 under the conditions of the assay. The majority of the
compounds synthesised showed greater than 20 fold selectivity for
T. b. brucei growth inhibition over mammalian HepG2 cytotoxicity.
In general compounds that showed more potent inhibition of TAO
showed better a better selectivity index over mammalian HepG2
cells (see Table 3).3. Conclusions
Despite current efforts, HAT remains a considerable threat to the
health and well-being of those infected. Currently available treat-
ments are far from safe with increasing incidences of drug resis-
tance being reported. Ascofuranone was described as a nanomolar
inhibitor of TAO in the late 1990s [27], however exploitation of this
opportunity has been severely limited due to the availability of
robust synthetic routes to these molecules. With the potential to
assist future drug development of the ascofuranone chemotype weTable 3
Alkylation of phenols.
# R1 R5 TAO inhibition (pIC
34 O-Geranyl OH 6.0 ± 0.1
35 OH O-Geranyl 6.6 ± 0.2
a Negative log concentration and standard deviation of compounds required for 50% i
b Negative log concentration and standard deviation of compounds required for 50% g
c Negative log concentration and standard deviation of compounds required for 50% gpresent 3 novel and versatile synthetic approaches, together with
the SAR ﬁndings developed during our synthetic exploration. These
routes offer signiﬁcantly improved yields over previous methods
and importantly, allow late stage diversiﬁcation of the crucial ar-
omatic head group that is responsible for both the afﬁnity for the
enzyme and the undesirable, non-drug-like functionality. The SAR
presented builds on that previously published [26], demonstrating
that the aromatic pharmacophore is more amenable to alteration
than previously reported. These synthetic and SAR ﬁndings provide
the foundations for onward exploitation of this chemotype towards
novel treatments for HAT via inhibition of TAO and our onward
investigation further aims to develop CNS drug-like leads from
these challenging chemical starting points.4. Experimental section
Experimental Details. ChemAxon Calculator Plugins were used
for structure property prediction and calculation (clogP), Marvin
15.5.4, 2015, ChemAxon (http://www.chemaxon.com). All com-
mercial reagents were purchased from Sigma-Aldrich, Alfa Aesar,
Apollo Scientiﬁc, Fluorochem or Tokyo Chemical Industry and of
the highest available purity. Unless otherwise stated, chemicals
were used as supplied without further puriﬁcation. Anhydrous
solvents were purchased from Acros (AcroSeal™) or Sigma-Aldrich
(SureSeal™) and were stored under nitrogen. 40e60 petrol ether
refers to the fraction with a boiling point between 40 C and 60 C.
Anhydrous solvents and reagents were used as purchased. Thin
layer chromatography (TLC) was carried out using glass plates pre-50)a T.b.b. Growth inhibition (pIC50)b HepG2 Cytotox
(pCC50)c
5.5 ± 0.1 4.7 ± 0.1
4.9 ± 0.1 5.0 ± 0.1
nhibition of trypanosome alternative oxidase.
rowth inhibition of T. b. brucei Lister427.
rowth inhibition of HepG2 cell line.
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mined using an OptiMelt apparatus and are uncorrected. Proton
nuclearmagnetic resonance spectrawere recorded at 500MHz on a
Varian VNMRS 500 MHz spectrometer (at 30 C), using residual
isotopic solvent (CHCl3, dH¼ 7.27 ppm, DMSO dH¼ 2.50 ppm,MeOH
dH ¼ 3.31 ppm) as an internal reference. Chemical shifts are quoted
in parts per million (ppm). Coupling constants (J) are recorded in
Hertz (Hz). Carbon nuclear magnetic resonance spectra were
recorded at 125 MHz on a Varian 500 MHz spectrometer and are
proton decoupled, using residual isotopic solvent (CHCl3,
dC ¼ 77.00 ppm, DMSO dC ¼ 39.52 ppm, MeOH dC ¼ 49.00 ppm) as
an internal reference. Proton and carbon spectra assignments are
supported by DEPT editing. Chemical shifts (dC) are quoted in ppm.
High resolutionmass spectrometry (HRMS) data (ESI) was recorded
on Bruker Daltonics, Apex III, ESI source: Apollo ESI with methanol
as spray solvent. Onlymolecular ions, fractions frommolecular ions
and other major peaks are reported as mass/charge (m/z) ratios.
LCMS data was recorded on a Waters 2695 HPLC using a Waters
2487 UV detector and a Thermo LCQ ESI-MS. Samples were eluted
through a Phenomenex Lunar 3 mm C18 50 mm  4.6 mm column,
using water and acetonitrile acidiﬁed by 0.1% formic acid at 1 ml/
min and detected at 254 nm. The gradient employed was a 7 min
method 30e90%MeCN over a 5 min gradient, held at 90%MeCN for
1 min, then re-equilibrated to 30% MeCN over 1 min. All experi-
ments were carried out under an inert atmosphere of N2 unless
otherwise stated.
Absorbance Assay. 1-Ubiquinol turnover was measured by
recording the increase in absorbance at 278 nm (Greiner 96-well
UV star ﬂat bottom plates with BMG PHERAstar FS photo spec-
trometer) to monitor the increase of 1-Ubiquinone concentration
kinetically over 6 min with puriﬁed rTAO (3 nM), The Michalis-
Menten derived Km of 1-Ubiquinol showed to be 16.5 mM, kinetic
measurements at high (>250 mM) concentrations of substrate
showed higher rates of enzyme product formation, this was also
observed with high substrate concentrations without enzyme. It
was therefore necessary to carry out a background subtraction of
substrate turnover without enzyme to generate accurate Michalis-
Menten Km calculations. A ﬁnal concentration of 15 mM 1-
Ubiquinol was used under the following conditions: 50 mM Tris-
HCl; 0.05% (w/v) C10E8; pH 7.4; 25 C). The sigmoidal curve of
the inhibitionwas observed by 10-point 3 fold serial dilution of test
compounds to generate IC50 values.
Growth inhibition assays. Bloodstream form Trypanosoma
brucei brucei Lister 427 parasites were continuously passaged in
HMI-9 medium formulated from IMDM medium (Invitrogen), 10%
heat-inactivated fetal bovine serum, 10% Serum Plus medium
supplement (SAFC Biosciences), 1 mM hypoxanthine (Sigma-
Aldrich), 50 mM bathocuproine disulfonic acid (Sigma-Aldrich),
1.5 mM cysteine (Sigma-Aldrich), 1 mM pyruvic acid (Sigma-
Aldrich), 39 mg/mL thymidine (Sigma-Aldrich), and 14 mL/L beta-
mercapthoethanol (Sigma-Aldrich); all concentrations of added
components refer to that in complete HMI-9medium. The parasites
were cultured in 10 mL of HMI-9 medium in T75 CELL-STAR tissue
culture ﬂasks at 37 C/5% CO2.
To determine growth inhibitory potency of compounds against
T. b. brucei bloodstream form parasites, 200 nL of 10-point, 3 fold
serially diluted compounds in DMSO were transferred to the wells
of white, solid bottom 384-well plates (Greiner Bio-One) by either
Echo 555 acoustic liquid handling system or Mosquito. Then, 104 of
T. b. brucei parasites in 40 mL of HMI-9 mediumwere added to each
well, and the plates were incubated for 48 h at 37 C in 5% CO2
incubators. Parasite numbers in individual plate wells were deter-
mined through quantiﬁcation of intracellular ATP amount. The
CellTiter-Glo luminescent cell viability reagent (Promega) was
added to plate wells, and ATP-dependent luminescence signal wasmeasured on Tecan M1000 plate Reader after 30 min incubation.
Suramin an anti-trypanosomal drug was used positive control and
DMSO was used as negative control. pIC50 values were calculated
using Graph Pad Prism software by plotting the luminescence
values in sigmoidal dose response curves. Suramin was used as a
positive control in screening. (pIC50e6.7 ± 0.1).
Hep-G2 Cytotoxicity Assay. Human hepatocellular carcinoma
(HepG2) cells were obtained from ATCC and grown in RPMI media.
25 mL of 1.6  104 cells/mL were dispensed into sterile 384 well
Griener clear plates and incubated at 37 C in 5% CO2 incubator for
24 h. Once the cells adhered, 125 nL of 10-point, 3 fold serially
diluted compounds in DMSO were transferred on to cells. After
incubating for additional 96 h at 37 C in 5% CO2 incubator, cells
were added with CCK-8 reagent to each well. Plates were further
incubated for 3 h followed by absorbance reading at 450 nM using
Envision reader. Absorbance values were used for determination of
cytotoxic concentration (pCC50) required to inhibit 50% growth.
Purmycin was used as positive control in screening
(pIC50e6.3 ± 0.1).4.1. Synthesis
4.1.1. 2-Chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-4-
formyl-3-methylphenyl acetate (5)
To a suspension of 3-chloro-4,6-dihydroxy-2-
methylbenzaldehyde (4) [35] [36] (11.8 g, 63.2 mmol) in DCM
(300 mL) was added trimethylamine (8.8 mL, 63.2 mmol) at room
temperature. This mixture was stirred for 15 min during which
time the suspension had dissolved. Acetyl chloride (4.5 mL,
63.3 mmol) was added to the reaction mixture dropwise at room
temperature over 20 min and this was stirred for a further 5 h.
Deionised water (200 mL) was added and the phases were sepa-
rated. The aqueous layer was extracted with ethyl acetate
(3  100 mL) and the combined organic extracts were dried over
magnesium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation 2 times by ﬂash column chromatography
(100 g silica), eluting with a gradient of petrol ether: ethyl acetate
(95: 5) to (90: 10), gave 2-chloro-4-formyl-5-hydroxy-3-
methylphenyl acetate as an off-white solid (9.9 g, 68%): Rf 0.46
(10% ethyl acetate/90% 40e60 petrol ether); 1H NMR (500 MHz,
Chloroform-d) d 12.16 (s, 1H), 10.31 (s, 1H), 6.70 (s, 1H), 2.68 (s, 3H),
2.37 (s, 3H).
To a solution of 2-chloro-4-formyl-5-hydroxy-3-methylphenyl
acetate (1.30 g, 5.7 mmol) and geranyl bromide (1.35 mL,
6.8 mmol) in dimethylformamide (10 mL) was added potassium
iodide (85 mg, 0.6 mmol) followed by potassium carbonate (2.35 g,
17.1 mmol). The reaction mixture was stirred at room temperature
for 16 h before being diluted with deionised water (50 mL). This
mixture was extracted with diethyl ether (3  30 mL) and the
combined organic extracts were dried over magnesium sulfate,
ﬁltered and concentrated under reduced pressure. Puriﬁcation by
ﬂash column chromatography (25 g silica), eluting with a gradient
of petrol ether: ethyl acetate (100: 0) to (90: 10), gave the title
compound as a yellow oil (1.04 g, 50%) and 4-chloro-5-{[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]oxy}-2-formyl-3-methylphenyl ace-
tate (710 mg, 41%).4.1.2. 2-Chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-4-
formyl-3-methylphenyl acetate (5)
Rf 0.46 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.56 (s, 1H), 6.71 (s, 1H), 5.51e5.40 (m,
1H), 5.13e5.05 (m, 1H), 4.60 (d, J ¼ 6.6 Hz, 2H), 2.67 (s, 3H), 2.38 (s,
3H), 2.22e1.97 (m, 4H), 1.73 (s, 3H), 1.69 (s, 3H), 1.62 (s, 3H). LCMS
(ESI) retention time 6.64 min, m/z 365.77/367.26.
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formyl-3-methylphenyl acetate (5)
Rf 0.28 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.26 (s, 1H), 6.58 (s, 1H), 5.57e5.41 (m,
1H), 5.09 (t, J¼ 6.1 Hz, 1H), 4.67 (d, J¼ 6.5 Hz, 2H), 2.72 (s, 3H), 2.38
(s, 3H), 2.18e2.07 (m, 4H),1.76 (s, 3H),1.69 (s, 3H),1.62 (s, 3H). LCMS
(ESI) retention time 6.64 min, m/z 365.59/367.66.
4.1.4. 3-Chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-
dihydroxy-2-methylbenzaldehyde (6)
(colletochlorin B) To a solution of 2-chloro-5-{[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]oxy}-4-formyl-3-methylphenyl ace-
tate (5) (757 mg, 2.1 mmol) in toluene (7.5 mL) was added Fluorosil
(100e200 mesh, 2.3 g). The reaction mixture was heated at reﬂux
for 3 h before being allowed to cool to room temperature and being
ﬁltered. The Fluorosil was washed with ethyl acetate (3  15 mL)
and the combined ﬁltrate was concentrated under reduced pres-
sure. Puriﬁcation by ﬂash column chromatography (25 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (95:
5), gave 2-chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-
formyl-5-hydroxy-3-methylphenyl acetate as a colourless oil
(212 mg, 28%): Rf 0.67 (5% ethyl acetate/95% 40e60 petrol ether);
1H NMR (500 MHz, Chloroform-d) d 12.53 (s, 1H), 10.31 (s, 1H),
5.21e4.96 (m, 2H), 3.35e3.25 (m, 2H), 2.66 (s, 3H), 2.38 (s, 3H),
2.09e2.01 (m, 2H), 2.01e1.93 (m, 2H), 1.75 (s, 3H), 1.66 (s, 3H), 1.59
(s, 2H).
To a solution of 2-chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-5-hydroxy-3-methylphenyl acetate (110 mg,
0.3 mmol) in THF (4 mL) and MeOH (1 mL) was added 1 M aqueous
sodium hydroxide (1.5 mL, 1.5 mmol). The reaction mixture was
stirred at room temperature for 3 h during which time the reaction
mixture turned deep purple. The reaction mixture was acidiﬁed to
pH 1 with 1 M aqueous HCl and the reaction colour faded to yellow.
This mixture was extracted with ethyl acetate (3  10 mL) and the
combined organic extracts were dried over magnesium sulfate,
ﬁltered and concentrated under reduced pressure. Puriﬁcation by
ﬂash column chromatography (10 g silica), eluting with a gradient
of petrol ether: ethyl acetate (100: 0) to (95: 5), gave the title
compound as an off-white solid (93 mg, 97%): Rf 0.48 (5% ethyl
acetate/95% 40e60 petrol ether); 1H NMR (500 MHz, Chloroform-
d) d 12.70 (s, 1H), 10.16 (s, 1H), 6.42 (s, 1H), 5.29e5.17 (m, 1H),
5.09e5.05 (m, 1H), 3.42 (d, J ¼ 7.1 Hz, 2H), 2.61 (s, 3H), 2.13e2.03
(m, 2H), 2.03e1.97 (m, 2H), 1.80 (s, 3H), 1.66 (d, J ¼ 1.4 Hz, 3H), 1.59
(s, 3H).
4.1.5. 1,3-Bis(methoxymethoxy)-5-methylbenzene (8)
60% Sodium hydride in mineral oil (742 mg, 18.5 mmol) was
added in three portions to a stirred solution of orcinol (7) (1.00 g,
8.1 mmol) in DMF (20 mL) at 0 C. This was stirred for 40 min and
methyl chloromethoxy ether (1.35 mL, 17.7 mmol) added dropwise.
The reaction was stirred for 16 h and then diluted with water
(100 mL) and extracted with diethyl ether (3  100 mL). The
combined ether fractions werewashed with 1 M sodium hydroxide
solution (50 mL), saturated brine solution (50 mL), dried over so-
dium sulfate, ﬁltered and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography (20 g silica), eluting
with a gradient of 40e60 petrol ether: ethyl acetate (100: 0) to (95:
5), gave the title compound as a clear oil (1.59 g, 93%): 1H NMR
(500 MHz, chloroform-d) d 6.56 (1 H, s), 6.54 (2H, s), 5.15 (4 H, s),
3.49 (6 H, s), 2.31 (3 H, s); HRMS (ESI) calcd 212.1049 for C11H16O4
[MþH]þ, found 212.1047 m/z.
4.1.6. (E)-3-(3,7-Dimethylocta-2,6-dienyl)-2,4-
bis(methoxymethoxy)-6-methylbenzaldehyde (9)
3-Bis(methoxymethoxy)-5-methylbenzene (8) (2.50 g,11.8 mmol) was dissolved in dry tetrahydrofuran (90 mL) and
cooled to 0 C. 2.1 M n-butyl lithium (8.41 mL, 17.7 mmol) was
added drop-wise and the reaction was left to stir for 1 h at 0 C.
Geranyl bromide (4.48 g, 20.6 mmol) was added to the reaction
mixture in a drop-wisemanner. This was stirred for 1 h and allowed
to come to room temperature. The reactionwas cooled to 0 C again
and 2.1 M n-butyl lithium (8.41 mL, 17.7 mmol) added followed by
another 1 h stirring at 0 C. Excess dry DMF was added and the
reaction was allowed to come to room temperature over 1 h. The
reaction was diluted with water (300 mL) and extracted with
diethyl ether (3  200 mL). The combined organics were dried over
sodium sulfate, ﬁltered and concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography (50 g silica), eluting
with a gradient of 40e60 petrol ether: ethyl acetate (100:0) to
(95:5), gave the title compound as a yellow tinted clear oil (1.28 g,
31%): 1H NMR (500MHz, chloroform-d) d 10.38 (1 H, s), 6.74 (1 H, s),
5.24 (2 H, s), 5.17 (1 H, t, J ¼ 6.6 Hz), 5.04 (2 H, s), 5.01 (1 H, t,
J ¼ 6.4 Hz), 3.57 (3 H, s), 3.46 (3 H, s), 3.36 (2 H, d, J ¼ 6.7 Hz), 2.57
(3 H, s), 2.05 (2 H, m), 1.97 (2 H, m), 1.76 (3 H, s), 1.63 (3 H, s), 1.56
(3 H, s); IR (neat, nmax) cm1 2932, 1682, 1595, 1560, 1440, 1375,
1315, 1284, 1220, 1152, 1039, 1007, 924; HRMS (ESI) calcd 399.2142
for C23H32NaO5 [MþNa]þ, found: 399.2147 m/z.
4.1.7. 5-Methyl-2-octylbenzene-1,3-diol (10)
3-Bis(methoxymethoxy)-5-methylbenzene (8) (2.00 g,
9.4 mmol) was dissolved in dry tetrahydrofuran (60 mL) and cooled
to 0 C. 2.5 M n-butyl lithium (4.90 mL, 12.3 mmol) was added
dropwise and the reactionwas left to stir for 1 h at 0 C. Iodooctane
(2.55 mL, 14.1 mmol) was added to the reaction mixture and this
was stirred for 1 h before being allowed to come to room temper-
ature. The reaction was diluted with water (300 mL) and extracted
with diethyl ether (3  200 mL). The organic fractions were dried
over sodium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (25 g silica),
eluting 40e60 petrol ether: ethyl acetate (100: 0) to (95: 5), gave
1,3-bis(methoxymethoxy)-5-methyl-2-octylbenzene as a colour-
less oil (2.54 g, 83%): Rf 0.79 (10% ethyl acetate/90% 40e60 petrol
ether); 1H NMR (500 MHz, chloroform-d) d 6.59 (2 H, s), 5.17 (4 H,
s), 3.49 (6 H, s), 2.64 (2 H, t, J ¼ 8.0 Hz), 2.30 (3 H, s), 1.50 (2 H, m),
1.32 (10 H, m), 0.89 (3 H, t, J ¼ 6.8 Hz); 13C NMR (126 MHz,
chloroform-d) d 155.7, 136.6, 118.4, 108.7, 94.5, 75.4, 56.0, 31.9, 29.8,
29.7, 29.5, 29.3, 23.2, 22.7, 21.8, 14.1; IR (neat, nmax) cm1 2924,
2854, 1612, 1586, 1463, 1394, 1154, 1122, 1036, 923, 823; HRMS
(ESI): calcd. 347.2198 for C19H32NaO4 [MþNa]þ, found 347.2187m/z.
1,3-Bis(methoxymethoxy)-5-methyl-2-octylbenzene (350 mg,
1.1 mmol) was suspended in ethylene glycol (10 mL) and heated to
160 C by microwave irradiation for 5 h in sealed vial. The reaction
mixture was diluted with water (40 mL) and extracted with diethyl
ether (3  30 ml). The combined extracts were washed with water
(30 mL), dried over magnesium sulfate, ﬁltered and concentrated
under reduced pressure. Puriﬁcation by ﬂash column chromatog-
raphy (10 g silica), eluting 40e60 petrol ether: ethyl acetate (100: 0)
to (70: 30), gave the title compound as an orange/white powder
(220mg, 86%, m.p. 63e66 C): Rf 0.32 (10% ethyl acetate/90% 40e60
petrol ether); 1H NMR (500 MHz, chloroform-d) d 6.23 (2 H, s), 4.69
(2 H, s), 2.59 (2 H, t, J ¼ 7.9 Hz), 2.22 (3 H, s), 1.60e1.51 (2 H, m),
1.43e1.23 (10 H, m), 0.89 (3 H, t, J ¼ 6.8 Hz); 13C NMR (126 MHz,
chloroform-d) d 154.4, 137.0, 112.4, 108.7, 75.4, 31.9, 29.8, 29.5, 29.3,
23.0, 22.7, 21.0, 14.1. IR (neat, nmax) cm1 3427, 3280, 2956, 2918,
2850,1635,1584,1522,1467,1328,1268,1160,1112, 829, 534; HRMS
(ESI): calcd. 237.1849 for C15H25O2 [MþH]þ, found 237.1853 m/z.
4.1.8. 3-Chloro-4,6-dihydroxy-2-methyl-5-octylbenzaldehyde (11)
5-Methyl-2-octyl-benzene-1,3-diol (10) (500mg, 2.1 mmol) was
dissolved in dry DMF (4.08 mL, 52.9 mmol) and cooled to 0 C.
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syringe and the reaction was then allowed to come to room tem-
perature. The reaction was followed by thin layer chromatography
(20% ethyl acetate in 40e60 petroleum ether) and upon completion
after 2 h the reaction was cooled to 0 C and diluted with 1 M
aqueous sodium hydroxide solution (10 mL). This was stirred for
5 min then acidiﬁed with 1 M aqueous hydrogen chloride solution
(30 mL) and transferred to a separating funnel. The mixture was
then extracted with diethyl ether (3  20 mL). The combined
organic layers were washed with water (50 mL) and brine (50 mL).
The organics were dried over magnesium sulfate and concentrated
to dryness under reduced pressure. Puriﬁcation by ﬂash column
chromatography (10 g silica), eluting 40e60 petrol ether: ethyl
acetate (100: 0) to (80: 20), gave 2,4-dihydroxy-6-methyl-3-
octylbenzaldehyde as an orange/white powder (559 mg, 95%,
m.p. 101e103 C): Rf 0.18 (10% ethyl acetate/90% 40e60 petrol
ether); 1H NMR (500MHz, chloroform-d) d 12.63 (1 H, s),10.09 (1 H,
s), 6.20 (1 H, s), 5.52 (1 H, s), 2.60 (2 H, d, J ¼ 7.1 Hz), 2.50 (3 H, s),
1.59e1.47 (2 H, m), 1.42e1.21 (10 H, m), 0.89 (3 H, d, J ¼ 6.9 Hz); 13C
NMR (126 MHz, chloroform-d) d 193.0, 164.2, 161.0, 141.5, 114.0,
113.4, 110.2, 31.9, 29.7, 29.5, 29.3, 28.7, 22.6, 22.0, 17.9, 14.1; IR (neat,
nmax) cm1 3111, 2916, 2849, 1605, 1509, 1466, 1284, 1250, 1216,
1135, 829, 773, 644, 567; HRMS (ESI): calcd. 265.1804 for C16H25O3
[MþH]þ, found 265.1805 m/z.
2,4-Dihydroxy-6-methyl-3-octylbenzaldehyde (70 mg,
0.3 mmol) was dissolved in dry diethyl ether (5 mL) and sulfuryl
chloride (32 mL, 0.4 mmol) added. The reactionwas stirred for 1 h at
room temperature before being quenched with 1 M aqueous so-
dium hydroxide (5 mL). The mixture was then extracted with
diethyl ether (2  15 mL). The combined organic phases were dried
over magnesium sulfate, ﬁltered and concentrated on celite (1 g).
Puriﬁcation by ﬂash column chromatography over silica (10 g)
eluting 40e60 petrol ether: ethyl acetate (100: 0) to (80: 20) gave
the title compound as a white powder (65 mg, 81%, m.p. 65 C): Rf
0.58 (10% ethyl acetate/90% 40e60 petrol ether); 1H NMR
(500 MHz, chloroform-d) d 12.65 (1 H, s), 10.14 (1 H, s), 6.34 (1 H, s),
2.69 (2 H, d, J ¼ 7.1 Hz), 2.60 (3 H, s), 1.54e1.47 (2 H, m), 1.30e1.23
(10 H, m), 0.88 (3 H, d, J ¼ 6.9 Hz); 13C NMR (126 MHz, chloroform-
d) d 193.1,162.5,156.2,137.2,115.8, 113.5, 113.0, 31.9, 29.6, 29.5, 29.3,
28.4, 22.9, 22.6, 14.4, 14.1; IR (neat, nmax) cm1 3327, 2924, 2856,
1606, 1452, 1416, 1374, 1233, 1132, 791, 767, 710, 555; HRMS (ESI):
calcd. 299.1414 for C16H24ClO3 [MþH]þ, found 299.1421 m/z.4.1.9. Tert-butyl-3-(4-methyl-2,6-dioxocyclohexyl)propanoate (12)
5-Methylcyclohexane-1,3-dione (2.00 g, 15.9 mmol) and t-butyl
acrylate (2.55 mL, 17.4 mmol) were dissolved in N,N-dime-
thylformamide (10 mL) and sodium hydride (635 mg, 15.8 mmol)
added slowly. The reaction was stirred for 1 h at room temperature
then heated to 80 C for 16 h. The reactionwas allowed cool to room
temperature, acidiﬁed to pH 4with acetic acid then neutralised and
diluted with saturated aqueous sodium hydrogen carbonate solu-
tion (30 mL). This was extracted with ethyl acetate (3 30 mL). The
combined organics were washed with saturated aqueous sodium
hydrogen carbonate (30mL), dried over magnesium sulfate, ﬁltered
and concentrated under reduced pressure onto celite (4 g). Puriﬁ-
cation by ﬂash column chromatography over silica (25 g) eluting
40e60 petrol ether: ethyl acetate (100:0) to (60:40) gave the title
compound as a pale yellow powder (2.94 g, 73%). Product was
unstable, full characterisation after subsequent reaction to tert-
butyl 3-(2-methoxy-4-methyl-6-oxocyclohex-1-en-1-yl)prop-
anoate (14): 1H (500 MHz, chloroform-d) d 2.49e2.36 (6 H, m),
2.18e2.02 (3 H, m), 1.42 (9 H, s), 1.02 (3 H, d, J ¼ 6 Hz); HRMS (ESI)
calcd 277.1410 for C14H22NaO4 [MþNa]þ, found: 277.1415 m/z.4.1.10. 5-Methyl-2-octylcyclohexane-1,3-diol (13)
5-Methylcyclohexane-1,3-dione (10.3 g, 81.9 mmol), octanal
(8.54 mL, 54.6 mmol) and L-proline (1.26 g, 10.9 mmol) were dis-
solved in ethanol (150 mL) and stirred for 1 h. Sodium cyanobor-
ohydride (3.43 g, 54.6 mmol) and molecular sieves (350 mg per
mmol of aldehyde) were added and the reaction heated to 80 C for
2 h. The reaction was poured onto ice (100 g) and the white solid
suspension that formed was vacuum ﬁltered. The solids were dis-
solved in ethyl acetate (40 mL) and washed with water (2 40 mL).
The organics were dried over magnesium sulfate, ﬁltered and
concentrated under reduced pressure to give the title compound as
a white powder (11.9 g, 91%) Product was a complex mixture of
isomers and full characterisation was conﬁrmed after successful
subsequent reaction to 3-methoxy-5-methyl-2-octylcyclohex-2-
enone (15): Rf 0.12 (20% ethyl acetate/80% 40e60 petrol ether);
HRMS (ESI) calcd 277.1410 for C15H27O2 [MþH]þ: found: 239.2005
m/z.
4.1.11. Tert-butyl-3-(2-methoxy-4-methyl-6-oxocyclohex-1-en-1-
yl)propanoate (14)
Tert-butyl 3-(2-hydroxy-4-methyl-6-oxo-cyclohexen-1-yl)
propanoate (12) (16.00 g, 62.9 mmol) and dimethyl sulfate (7.14mL,
75.5 mmol) were dissolved in tetrahydrofuran (200 mL) and so-
dium hydride (3.02 g, 75.5 mmol) added slowly. The reaction was
stirred at room temperature for 3 h then the reaction was
concentrated under reduced pressure and re-diluted with ethyl
acetate (25 mL) and water (25 mL). This mixture was neutralised
using excess sodium phosphate monobasic. The ethyl acetate was
separated and the aqueous layer extracted with more ethyl acetate
(2  30 mL). The combined organics were dried over magnesium
sulfate, ﬁltered and concentrated under reduced pressure onto
celite (2 g). Puriﬁcation by ﬂash column chromatography over silica
(100 g) eluting 40e60 petrol ether: ethyl acetate (100:0) to (80:20)
gave the title compound as a clear colourless oil (15.20 g, 90%). 1H
(600 MHz, choroform-d) d 3.78 (3 H, s), 2.69e2.58 (1 H, m),
2.55e2.43 (2 H, m), 2.43e2.34 (1 H, m), 2.24e2.17 (2 H, m),
2.17e2.09 (2 H, m), 2.05e1.93 (1 H, m), 1.40 (9 H, s), 1.07 (3 H, d, J
6.1).13C NMR (126 MHz, chloroform-d) d 197.6, 172.9, 171.5, 117.7,
79.6, 55.1, 44.7, 34.3, 33.0, 28.4, 28.1, 21.1, 17.8; IR (neat, nmax) cm1
2973, 1723, 1611, 1367, 1233, 1148, 1084, 846; HRMS (ESI): calcd.
291.1572 for C15H24NaO4 [MþNa]þ, found 291.1572 m/z.
4.1.12. 3-Methoxy-5-methyl-2-octylcyclohex-2-enone (15)
5-methyl-2-octyl-cyclohexane-1,3-dione (13) (567 mg,
2.4 mmol) was dissolved in dry methyl alcohol (5 mL) with 3 Å
molecular sieves (0.5 g) and 4-methylbenzenesulfonic acid (20 mg,
0.1 mmol) was added. The reaction was stirred for 24 h and then
was concentrated onto celite (2 g). Puriﬁcation by ﬂash column
chromatography over silica (10 g) eluting 40e60 petrol ether: ethyl
acetate (100:0) to (90:10) gave the title compound as a yellow oil
(257 mg, 43%): Rf 0.26 (20% ethyl acetate/80% 40e60 petrol ether);
1H (500 MHz, chloroform-d) d 3.80 (3 H, s), 2.71e2.61 (1 H, m), 2.44
(1 H, dd, J ¼ 15.7, 3.2 Hz), 2.28e2.11 (4 H, m), 2.07e1.98 (1 H, m),
1.26 (12 H, s), 1.10 (3 H, d, J ¼ 6.0 Hz), 0.88 (3 H, t, J ¼ 6.9 Hz); 13C
NMR (126 MHz, chloroform-d) d 198.0, 170.8, 119.6, 54.9, 44.8, 33.0,
31.8, 29.6, 29.4, 29.2, 28.6, 28.4, 22.6, 21.9, 21.1, 13.9. IR (neat, nmax)
cm1 2924, 1709, 1377, 1230, 1128, 1061, 1033, 722; HRMS (ESI):
calcd. 253.2168 for C16H29O2 [MþH]þ, found 253.2163 m/z.
4.1.13. Tert-butyl-3-(5-(hydroxymethylene)-2-methoxy-4-methyl-
6-oxocyclohex-1-en-1-yl)propanoate (16)
Diisopropylamine (4.62 mL, 32.9 mmol) was dissolved in dry
tetrahydrofuran (550 mL) and cooled to 78 C and 2.5 M n-
butyllithium (12.16 mL, 30.4 mmol) added. The reaction was
warmed to room temperature then cooled to 78 C and tert-butyl
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(6.8 g, 25.3 mmol) added. The reactionwas stirred for 1 h at 78 C
then methyl formate (2.34 mL, 38.0 mmol) was added and it was
allowed to warm to room temperature overnight. The reaction was
concentrated under reduced pressure, diluted water (50 mL) and
neutralised by careful addition of 1 M aqueous hydrogen chloride
solution. The organics were dried over magnesium sulfate, ﬁltered
and concentrated under reduced pressure onto celite (5 g). Puriﬁ-
cation by ﬂash column chromatography over silica (100 g) eluting
40e60 petrol ether: ethyl acetate (100:0) to (70:30) gave the title
compound as a yellow oil (4.41 g, 58.6%): Rf 0.22 (20% ethyl acetate/
80% 40e60 petrol ether); 1H NMR (500 MHz, chloroform-d)
d 7.21e7.07 (1 H, m), 3.79 (3 H, s), 2.76e2.69 (1 H, m), 2.67e2.60
(1 H, m), 2.60e2.56 (2 H, m), 2.35e2.25 (3 H, m), 1.41 (9 H, s), 1.16
(3 H, d, J ¼ 6.8 Hz); 13C NMR (126 MHz, chloroform-d) d 191.7, 172.7,
170.0, 160.3, 116.5, 111.2, 79.7, 55.2, 34.3, 32.0, 28.3, 28.1, 20.3, 17.5.
IR (neat, nmax) cm1 2972, 1721, 1607, 1366, 1241, 1146, 1080, 998,
847; HRMS (ESI): calcd. 319.1521 for C16H24NaO5 [MþNa]þ, found
319.1521 m/z.
4.1.14. 6-(Hydroxymethylene)-3-methoxy-5-methyl-2-
octylcyclohex-2-enone (17)
Diisopropylamine (2.67 mL, 19.0 mmol) was dissolved in dry
tetrahydrofuran (150 mL) and cooled to 78 C and n-butyllithium
(6.18 mL, 15.5 mmol) added. The mixture was allowed to warm to
room temperature and stirred for 30min. This was cooled to78 C
and a solution of 3-methoxy-5-methyl-2-octyl-cyclohex-2-en-1-
one (15) (3.00 g, 11.9 mmol) in dry tetrahydrofuran (5 mL) was
added via syringe. This was stirred for 1 h and dry methyl formate
(1.47 mL, 23.77 mmol) was added, the reaction was allowed to
warm to room temperature overnight slowly in the dry ice acetone
bath. The reaction mixture was concentrated under reduced pres-
sure and diluted with ethyl acetate (30 mL) and water (30 mL). This
was neutralised with 1 M aqueous hydrogen chloride, the ethyl
acetate separated and washed with water (30 mL). The organics
were dried over magnesium sulfate, ﬁltered and concentrated un-
der reduced pressure onto celite (2 g). Puriﬁcation by ﬂash column
chromatography over silica (25 g) eluting 40e60 petrol ether: ethyl
acetate (100:0) to (90:10) gave the title compound as a clear yellow
oil (2.25 g, 68%): Rf 0.46 (20% ethyl acetate/80% 40e60 petrol ether)
1H (500 MHz, chloroform-d) d 7.19 (1 H, d, J ¼ 1.2 Hz), 3.79 (3 H, s),
2.75 (1 H, q, J ¼ 6.7 Hz), 2.65 (1 H, dd, J ¼ 16.6, 6.1 Hz), 2.37e2.27
(3 H, m), 1.34 (2 H, m), 1.27 (10 H, m), 1.18 (3 H, d, J ¼ 6.8 Hz), 0.88
(3 H, t, J ¼ 6.8 Hz); 13C NMR (126 MHz, chloroform-d) d 191.9, 169.3,
160.5, 111.3, 55.0, 31.9, 31.8, 29.6, 29.4, 29.2, 28.6, 28.3, 22.6, 21.6,
20.4, 14.0. IR (neat, nmax) cm1 2923, 1608, 1378, 1238, 1159, 1130,
1006, 953; HRMS (ESI): calcd. 281.2117 for C17H29O3 [MþH]þ,
found 281.2113 m/z.
4.1.15. Tert-butyl-3-(3-formyl-2-hydroxy-6-methoxy-4-
methylphenyl)propanoate (18)
(Z)-tButyl 3-(5-(hydroxymethylene)-2-methoxy-4-methyl-6-
oxocyclohex-1-en-1-yl)propanoate (16) (1.00 g, 3.4 mmol) and
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.92 g, 4.1 mmol)
were dissolved in toluene (100 mL) and stirred for 16 h at room
temperature. The reaction was diluted with diethyl ether (200 mL),
the organics were washed with water (6  100 mL), dried over
magnesium sulfate, ﬁltered and concentrated under reduced
pressure onto celite (2 g). Puriﬁcation by ﬂash column chroma-
tography over silica (25 g) eluting 40e60 petrol ether: ethyl acetate
(100:0) to (70:30) gave the title compound as awhite solid (835mg,
84%, m.p. 58e59 C): Rf 0.36 (20% ethyl acetate/80% 40e60 petrol
ether); 1H (500 MHz, chloroform-d) d 12.41 (1 H, s), 10.13 (1 H, s),
6.28 (1 H, s), 3.89 (3 H, s), 2.95e2.86 (2 H, m), 2.57 (3 H, s),
2.45e2.38 (2 H, m), 1.44 (9 H, s). 13C NMR (126 MHz, chloroform-d)d 193.1, 172.7, 164.1, 162.9, 142.3, 114.1, 113.6, 105.2, 79.9, 55.7, 34.2,
28.1, 18.4, 17.8. IR (neat, nmax) cm1 2967, 1722, 1637, 1366, 1248,
1125, 1004, 816, 644; HRMS (ESI): calcd. 317.1365 for C16H22NaO5
[MþNa]þ, found 317.1363 m/z.
4.1.16. 2-Hydroxy-4-methoxy-6-methyl-3-octylbenzaldehyde (19)
6-(Hydroxymethylene)-3-methoxy-5-methyl-2-octylcyclohex-
2-enone (17) (77 mg, 0.3 mmol) and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (73 mg, 4.1 mmol) were dissolved in toluene (20mL)
and stirred for 16 h at room temperature. The reaction was diluted
with diethyl ether (50 mL), the organics were washed with water
(6  50 mL), dried over magnesium sulfate, ﬁltered and concen-
trated under reduced pressure onto celite (2 g). Puriﬁcation by ﬂash
column chromatography over silica (25 g) eluting 40e60 petrol
ether: ethyl acetate (100:0) to (70:30) gave the title compound as a
white solid (835 mg, 84%, m.p. 58e59 C): Rf 0.24 (20% ethyl ace-
tate/80% 40e60 petrol ether); 1H (500 MHz, chloroform-d) d 12.41
(1 H, s), 10.13 (1H, s), 6.28 (1H, s), 3.89 (3H, s), 2.95e2.86 (2H, m),
2.57 (3H, s), 2.45e2.38 (2H, m), 1.44 (9H, s). 13C NMR (126 MHz,
chloroform-d) d 193.1, 172.7, 164.1, 162.9, 142.3, 114.1, 113.6, 105.2,
79.9, 55.7, 34.2, 28.13, 18.4, 17.8. HRMS (ESI): calcd. 279.1955 for
C17H27O3 [MþH]þ, found 279.1948 m/z.
4.1.17. 2-Chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-formyl-
5-hydroxy-3-methylphenyl acetate (20)
To a solution of 2-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-4-formyl-3-methylphenyl acetate (5) (757 mg, 2.07 mmol)
in toluene (7.5 mL) was added Fluorosil (100e200 mesh, 2.3 g). The
reaction mixture was heated at reﬂux for 3 h before being allowed
to cool to room temperature and being ﬁltered. The Fluorosil was
washed with ethyl acetate (3  15 mL) and the combined ﬁltrate
was concentrated under reduced pressure. Puriﬁcation by ﬂash
column chromatography (25 g silica), eluting with a gradient of
petrol ether: ethyl acetate (100: 0) to (95: 5), gave the title com-
pound as a colourless oil (212 mg, 28%): Rf 0.67 (5% ethyl acetate/
95% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-d) d 12.53
(s, 1H), 10.31 (s, 1H), 5.21e4.96 (m, 2H), 3.35e3.25 (m, 2H), 2.66 (s,
3H), 2.38 (s, 3H), 2.09e2.01 (m, 2H), 2.01e1.93 (m, 2H), 1.75 (s, 3H),
1.66 (s, 3H), 1.59 (s, 2H). LCMS (ESI) retention time 6.83 min, m/z
365.43/367.21.
4.1.18. 5-Chloro-3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxybenzaldehyde (21)
To a solution of 6-chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-3-hydroxyphenyl acetate (22) (70.0 mg, 0.200 mmol)
in tetrahydrofuran (4 mL) and methanol (1 mL) was added 1 M
aqueous sodium hydroxide (1.0 mL, 1.00 mmol). The reaction
mixture was stirred at room temperature for 6 h before being
quenched with 1M aqueous hydrochloric acid (5 mL) and extracted
with ethyl acetate (3  10 mL). The combined organic fractions
dried over magnesium sulfate, ﬁltered and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography
(10 g silica), eluting with a gradient of petrol ether: ethyl acetate
(100: 0) to (90: 10), gave the title compound as an off-white solid
(55 mg, 89%): Rf 0.40 (5% ethyl acetate/95% 40e60 petrol ether) 1H
NMR (500 MHz, Chloroform-d) d 11.53 (s, 1H), 9.67 (s, 1H), 7.39 (s,
1H), 6.38 (s, 1H), 5.29e5.19 (m, 1H), 5.10e5.02 (m, 1H), 3.44 (d,
J ¼ 7.2 Hz, 2H), 2.13e2.04 (m, 2H), 2.04e1.97 (m, 2H), 1.81 (d,
J ¼ 1.5 Hz, 3H), 1.66 (d, J ¼ 1.7 Hz, 3H), 1.58 (s, 3H).
4.1.19. 6-Chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-formyl-
3-hydroxyphenyl acetate (22)
To a solution of 2-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-4-formylphenyl acetate (synthesised using the same
method to make 5) (430 mg, 1.22 mmol) in toluene (6.5 mL) was
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heated at reﬂux for 3 h before being allowed to cool to room
temperature and being ﬁltered. The Fluorosil was washed with
ethyl acetate (3  15 mL) and the combined ﬁltrate was concen-
trated under reduced pressure. Puriﬁcation 3 times by ﬂash column
chromatography (10 g silica), eluting with a gradient of petrol
ether: ethyl acetate (100: 0) to (95: 5), gave the title compound as a
pale yellow oil (78 mg, 18%): Rf 0.59 (5% ethyl acetate/95% 40e60
petrol ether) 1H NMR (500 MHz, Chloroform-d) d 11.41 (s, 1H), 9.82
(s, 1H), 7.51 (s, 1H), 5.13e5.08 (m, 1H), 5.08e5.04 (m, 1H), 3.34 (d,
J ¼ 7.0 Hz, 2H), 2.38 (s, 3H), 2.13e2.01 (m, 2H), 2.01e1.91 (m, 2H),
1.76 (s, 3H), 1.66 (s, 3H), 1.59 (s, 3H). LCMS (ESI) retention time
6.64 min, m/z 351.59/353.19.
4.1.20. 3-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-2,4-dihydroxy-6-
methylbenzaldehyde (23)
To a solution of 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-
formyl-3-hydroxy-5-methylphenyl acetate (24) (6.0 mg,
0.018 mmol) in tetrahydrofuran (0.5 mL) and methanol (0.12 mL)
was added 4 M aqueous sodium hydroxide (9 mL, 1.00 mmol). The
reaction mixture was stirred at room temperature for 3 h before
being acidiﬁed to pH 2 with 1 M aqueous hydrochloric acid and
extracted with ethyl acetate (3  3 mL). The combined organic
fractions dried over magnesium sulfate, ﬁltered and concentrated
under reduced pressure. Puriﬁcation by ﬂash column chromatog-
raphy (1 g silica), eluting with a gradient of petrol ether: ethyl ac-
etate (100: 0) to (90: 10), gave the title compound as a white solid
(2.7 mg, 51%): Rf 0.15 (10% ethyl acetate/90% 40e60 petrol ether) 1H
NMR (500 MHz, Chloroform-d) d 12.78 (s, 1H), 10.09 (s, 1H), 6.22 (s,
1H), 6.15 (s, 1H), 5.31e5.22 (m, 1H), 5.12e5.00 (m, 1H), 3.42 (d,
J ¼ 7.2 Hz, 2H), 2.51 (s, 3H), 2.19e2.01 (m, 4H), 1.82 (d, J ¼ 1.5 Hz,
3H), 1.69 (d, J ¼ 1.6 Hz, 3H), 1.60 (s, 3H). LCMS (ESI) retention time
5.73 min, m/z 289.67.
4.1.21. 2-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-4-formyl-3-
hydroxy-5-methylphenyl acetate (24)
To a solution of 3-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-
4-formyl-5-methylphenyl acetate (synthesised using the same
method to make 5) (300 mg, 0.908 mmol) in toluene (9.0 mL) was
added Fluorosil (100e200 mesh, 3.0 g). The reaction mixture was
heated at reﬂux for 3 h before being allowed to cool to room
temperature and being ﬁltered. The Fluorosil was washed with
ethyl acetate (3  10 mL) and the combined ﬁltrate was concen-
trated under reduced pressure. Puriﬁcation by ﬂash column chro-
matography (10 g silica), eluting with a gradient of petrol ether:
ethyl acetate (100: 0) to (80: 20) then by prep HPLC, gave the title
compound as a pale yellow oil (12 mg, 4%): Rf 0.28 (10% ethyl ac-
etate/90% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-d)
d 12.45 (s, 1H), 10.25 (s, 1H), 6.47 (s, 1H), 5.17e5.09 (m, 1H),
5.08e5.01 (m, 1H), 3.28 (d, J ¼ 7.0 Hz, 2H), 2.57 (s, 3H), 2.31 (s, 3H),
2.10e2.00 (m, 2H), 2.01e1.95 (m, 2H), 1.75 (s, 3H), 1.65 (d, J¼ 1.6 Hz,
3H), 1.58 (s, 3H). LCMS (ESI) retention time 6.44 min, m/z 331.72.
4.1.22. 3-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxybenzaldehyde (25)
To a solution of 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4-
formyl-3-hydroxyphenyl acetate (26) (130 mg, 0.411 mmol) in
tetrahydrofuran (4.0 mL) and methanol (1.0 mL) was added 4 M
aqueous sodium hydroxide (308 mL, 1.23 mmol). The reaction
mixture was stirred at room temperature for 3 h before being
diluted with deionised water (10 mL), acidiﬁed to pH 1 with 1 M
aqueous hydrochloric acid and extracted with ethyl acetate
(3 10mL). The combined organic fractions dried over magnesium
sulfate, ﬁltered and concentrated under reduced pressure. Puriﬁ-
cation by ﬂash column chromatography (10 g silica), eluting with agradient of petrol ether: ethyl acetate (100: 0) to (80: 20), gave the
title compound as a cream coloured solid (83mg, 73%): Rf 0.36 (20%
ethyl acetate/80% 40e60 petrol ether) 1H NMR (500 MHz, Chloro-
form-d) d 11.79 (s, 1H), 9.70 (s, 1H), 7.32 (d, J ¼ 8.7 Hz, 1H), 6.49 (d,
J ¼ 8.5 Hz, 1H), 6.21 (s, 1H), 5.34e5.21 (m, 1H), 5.11e4.98 (m, 1H),
3.47 (d, J ¼ 7.2 Hz, 2H), 2.18e2.02 (m, 4H), 1.83 (s, 3H), 1.68 (d,
J ¼ 1.7 Hz, 3H), 1.60 (s, 3H). LCMS (ESI) retention time 5.57 min,m/z
275.64.
4.1.23. 2-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-4-formyl-3-
hydroxyphenyl acetate (26)
To a solution of 3-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-
4-formylphenyl acetate (synthesised using the same method to
make 5) (520 mg, 1.64 mmol) in toluene (7.5 mL) was added Flu-
orosil (100e200 mesh, 2.6 g). The reaction mixture was heated at
reﬂux for 3 h before being allowed to cool to room temperature and
being ﬁltered. The Fluorosil was washed with ethyl acetate
(3  20 mL) and the combined ﬁltrate was concentrated under
reduced pressure. Puriﬁcation 2 times by ﬂash column chroma-
tography (10 g silica), eluting with a gradient of petrol ether: ethyl
acetate (100: 0) to (90: 10), gave the title compound as a pale
yellow oil (133 mg, 26%): Rf 0.50 (10% ethyl acetate/90% 40e60
petrol ether) 1H NMR (500 MHz, Chloroform-d) d 11.54 (s, 1H), 9.85
(s, 1H), 7.44 (d, J ¼ 8.5 Hz, 1H), 6.76 (d, J ¼ 8.4 Hz, 1H), 5.17e5.10 (m,
1H), 5.09e5.02 (m, 1H), 3.33 (d, J ¼ 7.0 Hz, 2H), 2.33 (s, 3H),
2.10e2.02 (m, 2H), 2.02e1.94 (m, 2H),1.77 (s, 3H), 1.65 (d, J¼ 1.8 Hz,
3H), 1.58 (s, 3H).
4.1.24. 5-Chloro-3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2-
hydroxybenzaldehyde (27)
To a solution of 5-chloro-2-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}benzaldehyde (synthesised using the same method to make
5) (300 mg, 1.02 mmol) in toluene (5.0 mL) was added Fluorosil
(100e200 mesh, 3.0 g). The reaction mixture was heated at reﬂux
for 3 h before being allowed to cool to room temperature and being
ﬁltered. The Fluorosil was washed with ethyl acetate (3  10 mL)
and the combined ﬁltrate was concentrated under reduced pres-
sure. Puriﬁcation 2 times by ﬂash column chromatography (10 g
silica), eluting with a gradient of petrol ether: ethyl acetate (100: 0)
to (99: 1), gave the title compound as a pale yellow oil (45 mg,15%):
Rf 0.12 (100% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-
d) d 11.22 (s, 1H), 9.84 (d, J¼ 0.8 Hz, 1H), 7.39 (d, J¼ 2.6 Hz, 1H), 7.35
(d, J ¼ 2.6 Hz, 1H), 5.37e5.23 (m, 1H), 5.17e5.05 (m, 1H), 3.37 (d,
J ¼ 7.4 Hz, 2H), 2.21e2.02 (m, 4H), 1.76e1.65 (m, 6H), 1.62 (s, 3H).
4.1.25. 3-[(2E)-3,7-Dimethylocta-2,6-dien-1-yl]-2,4,6-
trihydroxybenzaldehyde (28)
To a solution of 2,4,6-trihydroxybenzaldehyde (500 mg,
3.24 mmol) and geranyl bromide (536 mL, 2.70 mmol) in acetone
(30 mL) was added potassium carbonate (224 mg, 1.62 mmol). The
reaction mixture was heated at reﬂux for 5 h before being allowed
to cool to room temperature and being concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (10 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (60:
40), gave the title compound as a yellow solid (102mg,13%): Rf 0.36
(40% ethyl acetate/60% 40e60 petrol ether) 1H NMR (500 MHz,
Chloroform-d) d 12.25 (s, 1H), 10.04 (s, 1H), 7.65 (d, 1H), 7.22 (s, 1H),
5.90 (s, 1H), 5.29e5.23 (m, 1H), 5.05 (t, J ¼ 6.7 Hz, 1H), 3.33 (d,
J ¼ 7.3 Hz, 2H), 2.21e1.97 (m, 4H), 1.80 (s, 3H), 1.67 (s, 3H), 1.59 (s,
3H).
4.1.26. 3-Chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-
dihydroxy-2-methylbenzonitrile (29)
To a solution of 5-chloro-7-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-methyl-1,2-benzoxazol-6-ol (synthesised using the same
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room temperature was added 1 M aqueous sodium hydroxide
(1.4 mL, 1.4 mmol). The reaction mixture was stirred at room
temperature for 1 h before being acidiﬁed to pH 1with 1M aqueous
hydrochloric acid. Ethyl acetate (10 mL) was added and the phases
were separated. The aqueous phase was extracted with ethyl ace-
tate (2  10 mL) and the combined organic fractions were dried
over magnesium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (5 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (90:
10), gave the title compound as a colourless oil (17mg, 38%): Rf 0.40
(10% ethyl acetate/90% 40e60 petrol ether) 1H NMR (500 MHz,
Chloroform-d) d 6.24 (s, 1H), 6.17 (s, 1H), 5.28e5.19 (m, 1H),
5.09e5.02 (m, 1H), 3.46 (d, J ¼ 7.2 Hz, 2H), 2.52 (s, 3H), 2.21e2.02
(m, 4H), 1.86e1.78 (m, 3H), 1.70 (d, J¼ 1.3 Hz, 3H), 1.61 (d, J¼ 1.6 Hz,
3H). LCMS (ESI) retention time 5.43 min, m/z 320.15/322.07.
4.1.27. 2-Chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-
hydroxy-3,4-dimethylphenyl acetate (30)
To a solution of 2-chloro-6-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-5-hydroxy-3-methylphenyl acetate (20) (100 mg,
0.274 mmol) in dichloromethane (5 mL) was added triethylamine
(76 mL, 0.548 mmol) and acetyl chloride (39 mL, 0.548 mmol) at
room temperature. The reaction mixture was stirred at room
temperature for 3 h before being concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (10 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (80:
20), 3-(acetyloxy)-6-chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4-formyl-5-methylphenyl acetate as a pale yellow oil (30 mg,
27%): Rf 0.40 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.27 (s, 1H), 5.12e5.01 (m, 1H),
5.01e4.91 (m, 1H), 3.21 (d, J ¼ 6.6 Hz, 2H), 2.68 (s, 3H), 2.37 (s, 3H),
2.36 (s, 3H), 2.09e2.01 (m, 2H), 2.01e1.94 (m, 2H), 1.73 (d,
J ¼ 1.5 Hz, 3H), 1.67 (d, J ¼ 1.7 Hz, 3H), 1.59 (d, J ¼ 1.4 Hz, 3H). LCMS
(ESI) retention time 6.44 min, m/z no ionisation.
To a solution of 3-(acetyloxy)-6-chloro-2-[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]-4-formyl-5-methylphenyl acetate
(30mg, 0.073mmol) in tetrahydrofuran (1.0mL) was added sodium
borohydride (11 mg, 0.295 mmol). The reaction mixturewas stirred
at room temperature for 3 h before being diluted with deionised
water (1 mL), quenched with 1 M aqueous hydrochloric acid (3 mL)
and extractedwith ethyl acetate (3 10mL). The combined organic
extracts were dried over magnesium sulfate, ﬁltered and concen-
trated under reduced pressure. Puriﬁcation by ﬂash column chro-
matography (10 g silica), eluting with a gradient of petrol ether:
ethyl acetate (100: 0) to (90: 10), gave the title compound as an off-
white solid (15 mg, 58%): Rf 0.57 (10% ethyl acetate/90% 40e60
petrol ether) 1H NMR (500 MHz, Chloroform-d) d 5.43 (s, 1H),
5.22e5.12 (m, 1H), 5.09e4.97 (m, 1H), 3.28 (d, J ¼ 7.6 Hz, 2H), 2.36
(s, 3H), 2.33 (s, 3H), 2.18 (s, 3H), 2.15e2.04 (m, 4H), 1.81 (s, 3H), 1.69
(d, J ¼ 1.4 Hz, 3H), 1.61 (s, 3H). LCMS (ESI) retention time 6.43 min,
m/z no ionisation.
4.1.28. 5-Chloro-3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxybenzonitrile (31)
To a solution of triphenylphosphine (42 mg, 0.162 mmol) in
dichloromethane (2 mL) was added 2,3-dichloro-5,6-dicyano-p-
benzoquinone (37 mg, 0.162 mmol). The dark reaction mixture was
stirred at room temperature for 1 min during which time the colour
faded. 4-Chloro-2-2E)-3,7-dimethylocta-2,6-dien-1-yl]-6-
[(hydroxyimino)methyl]benzene-1,3-diol (32) (35 mg, 0.108 mmol)
in dichloromethane (0.5 mL) was added to the reactionmixture in 1
portion and this was stirred for 1 min before being concentrated
under reduced pressure. Puriﬁcation by ﬂash column chromatog-
raphy (10 g silica), eluting with a gradient of petrol ether: ethylacetate (100: 0) to (90: 10), gave 5-chloro-7-[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]-1,2-benzoxazol-6-ol as a white solid
(24 mg, 72%).
To a solution of 5-chloro-7-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-1,2-benzoxazol-6-ol in ethanol (2.1 mL) at room temperature
was added 1 M aqueous sodium hydroxide (0.69 mL, 0.69 mmol).
The reaction mixture was stirred at room temperature for 1 h
before being acidiﬁed to pH 1 with 1 M aqueous hydrochloric acid.
Ethyl acetate (10 mL) was added and the phases were separated.
The aqueous phase was extracted with ethyl acetate (2  10 mL)
and the combined organic fractions were dried over magnesium
sulfate, ﬁltered and concentrated under reduced pressure. Puriﬁ-
cation by ﬂash column chromatography (5 g silica), eluting with a
gradient of petrol ether: ethyl acetate (100: 0) to (90: 10), gave the
title compound as a light green oil (12 mg, 57%): Rf 0.09 (5% ethyl
acetate/95% 40e60 petrol ether) 1H NMR (500 MHz, Chloroform-d)
d 7.38 (s, 1H), 6.31 (s, 1H), 6.11 (s, 1H), 5.33e5.17 (m, 1H), 5.11e4.97
(m, 1H), 3.49 (d, J ¼ 7.4 Hz, 3H), 2.20e2.01 (m, 4H), 1.82 (s, 3H), 1.70
(s, 3H), 1.61 (s, 3H). LCMS (ESI) retention time 4.98 min,m/z 306.09.
4.1.29. 4-Chloro-2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-6-
[(hydroxyimino)methyl]benzene-1,3-diol (32)
To a solution of 3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-
dihydroxy-6-methylbenzaldehyde (23) (44 mg, 0.142 mmol) in
ethanol/deionised water/tetrahydrofuran (3:2:2, 0.5 mL) was
added sodium acetate (17 mg, 0.214 mmol) and hydroxylamine
hydrochloride (11 mg, 0.157 mmol). The reaction mixture was
stirred for 16 h before being concentrated under reduced pressure.
Puriﬁcation by ﬂash column chromatography (5 g silica), eluting
with a gradient of petrol ether: ethyl acetate (100: 0) to (90: 10),
gave the title compound as a white solid (37 mg, 80%): Rf 0.30 (5%
ethyl acetate/95% 40e60 petrol ether) 1H NMR (500 MHz, Chloro-
form-d) d 9.31 (s, 1H), 8.10 (s, 1H), 7.08 (s, 1H), 7.02 (s, 1H), 5.88 (s,
1H), 5.35e5.18 (m, 1H), 5.14e5.00 (m, 1H), 3.46 (d, J ¼ 7.2 Hz, 2H),
2.12e2.04 (m, 2H), 2.04e1.96 (m, 2H),1.81 (d, J¼ 1.5 Hz, 3H),1.66 (s,
3H), 1.59 (s, 3H). LCMS (ESI) retention time 5.40 min, m/z 324.09/
326.11.
4.1.30. 3-Chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-
dimethoxy-2-methylbenzaldehyde (33)
To a solution of 3-chloro-5-[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]-4,6-dihydroxy-2-methylbenzaldehyde (6) (30 mg,
0.0929 mmol) and potassium carbonate (128 mg, 0.929 mmol) in
acetone (2 ml) was added methyl iodide (57 mL, 0.929 mmol). The
reaction mixture was stirred at room temperature for 16 h before
being concentrated under reduced pressure. The residue was dis-
solved in ethyl acetate (5 mL) and deionised water (5 mL). The
phases were separated and the aqueous phase was extracted with
ethyl acetate (2  5 mL). The combined organic extracts were dried
over magnesium sulfate, ﬁltered and concentrated under reduced
pressure. Puriﬁcation by ﬂash column chromatography (5 g silica),
eluting with a gradient of petrol ether: ethyl acetate (100: 0) to (95:
5), gave the title compound as a yellow oil (16 mg, 49%): Rf 0.71 (5%
ethyl acetate/95% 40e60 petrol ether) 1H NMR (500 MHz, Chloro-
form-d) d 10.43 (s, 1H), 5.24e5.12 (m, 1H), 5.12e5.00 (m, 1H), 3.88
(s, 3H), 3.83 (s, 3H), 3.42 (d, J ¼ 7.0 Hz, 2H), 2.65 (s, 3H), 2.12e2.04
(m, 2H), 2.04e1.96 (m, 2H), 1.80 (s, 3H), 1.64 (s, 3H), 1.60e1.55 (m,
3H).
4.1.31. 3-Chloro-4-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-6-
hydroxy-2-methylbenzaldehyde (34)
To a solution of 4-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-2-formyl-3-methylphenyl acetate (50 mg, 0.137 mmol) in
tetrahydrofuran (2 mL) and methanol (0.5 ml) was added 4 M
aqueous sodium hydroxide (68 mL, 0.274 mmol). The reaction
R.A. West et al. / European Journal of Medicinal Chemistry 141 (2017) 676e689688mixture was stirred at room temperature for 2 h before being
diluted with deionised water (2 mL) and acidiﬁed to pH 2 with 1 M
aqueous hydrochloric acid. The reaction mixture was extracted
with ethyl acetate (3  3 mL). The combined organic extracts were
dried over magnesium sulfate, ﬁltered and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography
(10 g silica), eluting with a gradient of petrol ether: ethyl acetate
(100: 0) to (95: 5), gave the title compound as a white solid (31 mg,
70%): Rf 0.16 (5% ethyl acetate/95% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 12.59 (s, 1H), 10.16 (s, 1H), 6.36 (s, 1H),
5.53e5.43 (m, 1H), 5.14e5.03 (m, 1H), 4.67 (d, J ¼ 6.5 Hz, 2H), 2.63
(s, 3H), 2.22e2.05 (m, 4H), 1.76 (d, J¼ 1.4 Hz, 3H), 1.68 (d, J¼ 1.6 Hz,
3H), 1.61 (d, J¼ 1.5 Hz, 3H). LCMS (ESI) retention time 6.88 min,m/z
323.72/325.95.
4.1.32. 3-Chloro-6-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-4-
hydroxy-2-methylbenzaldehyde (35)
To a solution of 2-chloro-5-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-4-formyl-3-methylphenyl acetate (5) (50 mg, 0.137 mmol)
in tetrahydrofuran (2 mL) and methanol (0.5 ml) was added 4 M
aqueous sodium hydroxide (68 mL, 0.274 mmol). The reaction
mixture was stirred at room temperature for 2 h before being
diluted with deionised water (2 mL) and acidiﬁed to pH 2 with 1 M
aqueous hydrochloric acid. The reaction mixture was extracted
with ethyl acetate (3  3 mL). The combined organic extracts were
dried over magnesium sulfate, ﬁltered and concentrated under
reduced pressure. Puriﬁcation by ﬂash column chromatography
(10 g silica), eluting with a gradient of petrol ether: ethyl acetate
(100: 0) to (90: 10), gave the title compound as awhite solid (39mg,
88%): Rf 0.23 (10% ethyl acetate/90% 40e60 petrol ether) 1H NMR
(500 MHz, Chloroform-d) d 10.50 (s, 1H), 6.56 (s, 1H), 6.14 (s, 1H),
5.51e5.43 (m, 1H), 5.14e5.04 (m, 1H), 4.61 (d, J ¼ 6.5 Hz, 2H), 2.69
(s, 3H), 2.21e2.04 (m, 3H), 1.75 (d, J¼ 1.5 Hz, 3H), 1.69 (d, J¼ 1.8 Hz,
3H), 1.62 (s, 3H). LCMS (ESI) retention time 5.88 min, m/z 323.22/
325.21.
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